-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga·08/04/2026 16:30:05
Listen to the news
TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $275 to $300.